ESR1 and breast neoplasm: In this real-world cohort of more than 750 patients with ESR1-mutant breast tumors, the median time-to-next-treatment on elacestrant was 6.4 months overall and 8.8 months in patients with one or fewer prior lines of metastatic therapy.